



Where Hope is a Way of Life



Nader Hanna, MD, Chief of Surgical Oncology; William Regine, MD, Chief of Radiation Oncology; and Kevin Cullen, MD, Director of the Marlene and Stewart Greenebaum Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Cancer Center is a National Cancer Institute-designated cancer center, **one of the top cancer treatment and research centers in the country.** We offer **innovative approaches** to diagnosing and treating all types of cancer; conduct **cutting-edge research** to bring the **latest advances in cancer treatment** directly to our patients; and provide cancer screening and patient education services.

NATIONAL RECOGNITION:

NCI-designated Cancer Center – one of a select few in the U.S.

U.S. News & World Report's Top 50 Cancer Centers

Leapfrog Group Recognition – for outstanding quality and patient safety

Magnet Designation – for nursing excellence

SCIENTIFIC EXCELLENCE

Major advances in cancer research – including Dr. Angela Brodie's discovery of aromatase inhibitors, a new class of drugs for treating women with breast cancer, and Dr. Kevin Cullen's landmark study linking HPV to racial disparities in head-and-neck cancer survival

Pioneering stem cell and HIV/AIDS-related cancer studies – in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology

Innovative clinical trials – 150 active studies offering patients promising therapies, often years before they are available commercially

Active translational research program – designed to speed scientific discoveries from the laboratory to the clinic for the benefit of patients

State-of-the-art laboratories – where our researchers are developing cancer vaccines, novel cancer-fighting agents and promising combination therapies

Commitment to addressing cancer disparities – with research focused on improving access to care and treatment outcomes for minorities, who represent 36 percent of the patients in our clinical trials (compared to 2 percent nationally)

Major partnerships – with the state of Maryland, the National Cancer Institute, the American Cancer Society and private industry

OUTSTANDING PATIENT CARE

A team approach to care – specialists from all cancer disciplines work together to develop an individualized treatment plan for each patient

Minimally invasive treatment options – including Trilogy for radiation therapy, da Vinci robot-assisted surgery and the newest, targeted drug therapies

Patient-focused Stoler Pavilion outpatient center – designed for patients' comfort and convenience, with flat-screen TVs and Internet access

Top-rated nursing staff – specially trained in cancer care and consistently rated outstanding in patient satisfaction surveys

Support services for patients – including two full-time patient navigators, genetic and nutrition counseling, image renewal center and acupuncture for symptom management

Community outreach – free breast, cervical and colorectal cancer screenings for uninsured, low-income Baltimore residents through our Baltimore City Cancer Program

AT A GLANCE:

Patient visits annually 45,000
 Clinical trials 150
 Physicians and researchers 211
 Research funding \$62 million

COMPREHENSIVE TREATMENT PROGRAMS:

- Blood and Marrow Transplant
- Bone and Soft Tissue Oncology
- Brain Tumor Center
- Breast Evaluation and Treatment
- Gastrointestinal Oncology
- Genitourinary Oncology
- Gynecologic Oncology
- Head and Neck Oncology
- Hematologic Malignancies
- Skin Cancer (Cutaneous Oncology)
- Thoracic Oncology

